Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 9/20 | 0.53 |
| ▸ | NPY1R | P25929 | 7/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.53 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.52 |
| ▸ | GNPAT | O15228 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | NPY2R | P49146 | 3/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14050130 | 0.93 | KISS1R (0.56) | NPY4RNPY1RNPY5RKISS1RFOLH1 | |
| SCHEMBL6930854 | 0.91 | KISS1R (0.52) | NPY4RNPY1RNPY5RKISS1RFOLH1 | |
| SCHEMBL887778 | 0.90 | FOLH1 (0.45) | NPY4RNPY1RNPY5RKISS1RFOLH1 | |
| SCHEMBL28205670 | 0.88 | GRIA1 (0.59) | NPY4RNPY1RNPY5RKISS1RFOLH1 | |
| SCHEMBL30866924 | 0.87 | NPY4R (0.56) | NPY4RNPY1RNPY5RKISS1RGNPAT | |
| SCHEMBL10900796 | 0.87 | FOLH1 (0.67) | KISS1RFOLH1GNPATL3MBTL1 | |
| SCHEMBL31643144 | 0.87 | NPY4R (0.54) | NPY4RNPY1RNPY5RGNPATNPY2R | |
| SCHEMBL29462563 | 0.86 | NPY4R (0.52) | NPY4RNPY1RNPY5RKISS1RGNPAT | |
| SCHEMBL30866923 | 0.86 | NPY4R (0.62) | NPY4RNPY1RNPY5RKISS1RNPY2R | |
| SCHEMBL31420009 | 0.86 | GNPAT (0.56) | NPY4RNPY1RNPY5RGNPATNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2819702-A1 | NOVEL PRODRUG CONTAINING MOLECULE COMPOSTIONS AND THEIR USES | Ambrx, Inc. (US) | 2015-01-07 | — | — | EP | disclosed |
| WO-2013130814-A1 | NOVEL PRODRUG CONTAINING MOLECULE COMPOSTIONS AND THEIR USES | AMBRX, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| CN-101795675-A | Use has the colonic delivery that the Zn/ pectin beads of Eudragit coating carries out | DA VOLTERRA | 2010-08-04 | — | — | CN | disclosed |
| US-20100160209-A1 | Composition and Method for Increasing Cell Permeability of a Compound | SMITHKLINE BEECHAM CORPORATION (US) | 2010-06-24 | — | — | US | disclosed |
| EP-1771573-A4 | BIOSYNTHETIC POLYPEPTIDES UTILIZING NON-NATURALLY ENCODED AMINO ACIDS | AMBRX INC (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20080317666-A1 | Colonic Delivery of Active Agents | FATTAL ELIAS | 2008-12-25 | — | — | US | disclosed |
| US-20080312135-A1 | MIXTURES OF DRUG-OLIGOMER CONJUGATES COMPRISING POLYETHYLENE GLYCOL, USES THEREOF, AND METHODS OF MAKING SAME | EKWURIBE NNOCHIRI N | 2008-12-18 | — | — | US | disclosed |
| CN-101208099-A | Biosynthetic polypeptides utilizing non-naturally encoded amino acids | AMBRX INC (US) | 2008-06-25 | — | — | CN | disclosed |
| US-20080124279-A1 | Colonic delivery using Zn/pectin beads with a Eudragit coating | DA VOLTERRA FACULTE DE MEDECINE BICHAT (FR) | 2008-05-29 | — | — | US | disclosed |
| EP-1771573-A2 | BIOSYNTHETIC POLYPEPTIDES UTILIZING NON-NATURALLY ENCODED AMINO ACIDS | AMBRX, INC. (US) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006091231-A2 | BIOSYNTHETIC POLYPEPTIDES UTILIZING NON-NATURALLY ENCODED AMINO ACIDS | AMBRX, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| US-20060153801-A1 | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same | BIOCON LIMITED (IN) | 2006-07-13 | — | — | US | disclosed |
| US-7030082-B2 | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith | NOBEX CORPORATION (US) | 2006-04-18 | — | — | US | disclosed |
| US-20050136032-A1 | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same | BIOCON LIMITED (IN) | 2005-06-23 | — | — | US | disclosed |
| US-6858580-B2 | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same | NOBEX CORPORATION (US) | 2005-02-22 | — | — | US | disclosed |
| US-20040152769-A1 | Modified carbamate-containing prodrugs and methods of synthesizing same | BIOCON LIMITED (IN) | 2004-08-05 | — | — | US | disclosed |
| US-6770625-B2 | CONTAINING A FATTY ACID TO LOWER THE PRECIPITATION POINT OF BILE ACID SALT, WHICH IN TURN LOWERS THE SOLUBILITY OF THE FATTY ACID | NOBEX CORPORATION | 2004-08-03 | — | — | US | disclosed |
| US-20040017387-A1 | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith | BIOCON LIMITED (IN) | 2004-01-29 | — | — | US | disclosed |
| US-20030069170-A1 | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith | BIOCON LIMITED (IN) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060153801-A1 | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same | SI, SLC10A2, PIGO | NPY4R 3374/4885NPY1R 3781/4885NPY5R 3019/4885 |
| US-20050136032-A1 | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same | SI, SLC10A2, PIGO | NPY4R 3374/4885NPY1R 3781/4885NPY5R 3019/4885 |
| US-20030069170-A1 | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith | SLC10A1, SLC10A2, NR1H4 | NPY4R 2544/4885NPY1R 3265/4885NPY5R 1646/4885 |
| US-20040152769-A1 | Modified carbamate-containing prodrugs and methods of synthesizing same | DCTD, TST, CBR1 | NPY4R 896/4885NPY1R 462/4885NPY5R 765/4885 |
| US-20080312135-A1 | MIXTURES OF DRUG-OLIGOMER CONJUGATES COMPRISING POLYETHYLENE GLYCOL, USES THEREOF, AND METHODS OF MAKING SAME | SI, SLC10A2, FABP2 | NPY4R 3652/4885NPY1R 4148/4885NPY5R 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.